Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Future Oncology (London, England)|June 8, 2021
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancerDaniel P Petrylak, Raffaele Ratta, Rustem Gafanov, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 25, 2020
The prognostic impact of tumour NSD2 expression in advanced prostate cancerJudith Stangl-Kremser, Ursula Lemberger, Melanie R Hassler, et al.
Wiener Klinische Wochenschrift|August 30, 2008
[Chemotherapy for prostate cancer]Michael Rauchenwald, Maria De Santis, Eleonore Fink, et al.
Anti-Cancer Drugs|November 5, 2003
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinomaCatharina Wenzel, Gottfried J Locker, Rupert Bartsch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2020
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancerSazan Rasul, Markus Hartenbach, Tim Wollenweber, et al.
Urologia Internationalis|June 28, 2018
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate CancerChristopher Darr, Ulrich Krafft, Boris Hadaschik, et al.
Nuclear Medicine Communications|September 19, 2022
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastasesLucia Zisser, Josef Yu, André Oszwald, et al.
Wiener Klinische Wochenschrift|July 21, 2012
[Therapy of castration-resistant prostate cancer]Michael Rauchenwald, Thomas Bauernhofer, Maria De Santis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 30, 2019
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomyMohammad Abufaraj, Bernhard Grubmüller, Markus Zeitlinger, et al.
Cancers|June 2, 2021
Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate CancerSazan Rasul, Tim Wollenweber, Lucia Zisser, et al.
Pageof 12